Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer.

Abstract

Background: The addition of docetaxel to androgen deprivation therapy (ADT) for metastatic hormone sensitive prostate cancer (mHSPC) has demonstrated significant overall survival (OS) benefit. We aimed to evaluate the real-world utilisation rates of upfront docetaxel and associated patient outcomes in Australia. Annals of Oncology abstracts S1498 Volume 33 - Issue S9 - 2022 Methods: The electronic CRPC Australian Database (ePAD) was interrogated to identify patients diagnosed with mHSPC between July 2015 and July 2021. Clinicopathological features, treatment and outcome data, stratified by treatment with upfront docetaxel, were analysed through descriptive statistics. Survival analyses were calculated using the Kaplan-Meier method and groups compared using log-rank tests. Results: We identified 324 mHSPC patients with median age 69.8 years and median follow up 32.6 months. 152 (47%) received upfront docetaxel. 129 patients (85%) completed 6 cycles of docetaxel. Rates of docetaxel use were stable across a 6-year period (48% in 2015, 50% in 2021). Patients treated with docetaxel were significantly younger (mean 66 vs 74 years, p¼